Antoniv A. A.

CLINICAL AND EXPERIMENTAL MEDICINE

Scentific article

The aim of the study was to find out the probable effect of the comorbid flow of nonalcoholic steatohepatitis (NASH) on the functional state of the kidneys and the activity of inflammation of the kidneys in patients with chronic kidney disease (pyelonephritis) (CKD) of the I-III stage, to determine the pathogenetic role of endothelial dysfunction, lipid distress syndrome, endotoxicosis and oxidative stress in the mechanisms of their mutual burden. Object and methods of research. 240 patients with CKD (chronic bilateral peylonephritis) of the I-III stage were examined, 145 of which had comorbid NASH and obesity of the 1st degree (group 1), 95 patients were diagnosed with CKD І-ІІІ stages without comorbid pathology. Depending on the stage of the CKD, both groups were divided as follows: 1st group – into 3 subgroups: 51 patients with 1st stage CKD, 53 patients with 2nd stage CKD, 41 patients with 3rd stage CKD. The 2nd group was divided into 3 subgroups: 32 patients with 1st stage CKD, 35 patients with 2nd stage CKD, 28 patients with 3rd stage CKD. The control group consisted of 30 practically healthy persons. Results of research and their discussion. It was established that non-alcoholic steatohepatitis affects the functional state of the kidneys in patients with CKD І-ІІІ stages with a possible reduction of nitrogen function, velocity of glomerular filtration, increase in the intensity of hypoalbuminemia, proteinuria, leukocyturia, erythrocyturia, cylinduria, bacteriuria than in isolated course CKD. Conclusion. For the comorbidity of the CKD with NASH and a decrease in GFR, an increase in the intensity of oxidative stress, endotoxicosis, lipid distress syndrome, degree of violation of the functional state of the endothelium: increased activity of iNOS, nitrite/nitrate content, endothelin-1, homocysteine, cytokeratin-18, decrease in the activity of arginase, H2S content (p <0,05), which correlate with the intermediate and high power interactions with the index of GFR (p <0,05).

chronic kidney disease, nonalcoholic steatohepatitis, glomerular filtration rate, oxidative stress, endotoxicosis, lipid distress syndrome, functional state of the endothelium

1. Franchini S, Savino A, Marcovecchio ML, Tumini S, Chiarelli F, Mohn A. The effect of obesity and type 1 diabetes on renal function in children and adolescents. Pediatr. Diabetes. 2015;16:427-33.
2. Machado M, Gonçalves S, Carepa F, Coutinho J, Costa A, Cortez-Pinto H. Impaired renal function in morbid obese patients with nonalcoholic fatty liver disease. Liver Int. 2012 Feb;32(2):241-8.
3. Papademetriou M, Athyros G, Geladari E, Doumas M, Tsioufis C, Papademetriou V. The Co-Existence of NASH and Chronic Kidney Disease Boosts Cardiovascular Risk: are there any Common Therapeutic Options? Current Vascular Pharmacology. 2017;15:1-15.
4. Pacifico L, Bonci E, Andreoli GM, Michele Di M, Alessia G, Ester De Luca, et al. The Impact of Nonalcoholic Fatty Liver Disease on Renal Function in Children with Overweight/Obesity. Int. J. Mol. Sci. 2016;17:1218.
5. Babak OYa, Kolesnikova EV, Syitnik KA. Profilakticheskie meropriyatiya pri nealkogolnoy zhirovoy bolezni pecheni: suschestvuet li sposob snizit risk razvitiya zabolevaniya? Suchasna gastroenterol. 2013;3(71):103-9. [in Russian].
6. Cheng HT, Huang JW, Chiang CK, Yen CJ, Hung KY, Wu KD. Metabolic syndrome and insulin resistance as risk factors for development of chronic kidney disease and rapid decline in renal function in elderly. J. Clin. Endocrinol. Metab. 2012;97:1268-76.
7. Dai H, Wang W, Tang X, Chen R, Chen Z, Lu Y. Association of homocysteine level with biopsyproven non-alcoholic fatty liver disease: a metaanalysis. J. Clin. Biochem. Nutr. 2016;58(1):76-83.
8. Franchini S, Savino A, Marcovecchio ML, Tumini S, Chiarelli F, Mohn A. The effect of obesity and type 1 diabetes on renal function in children and adolescents. Pediatr. Diabetes. 2015;16:427-33.
9. Machado M, Gonçalves S, Carepa F, Coutinho J, Costa A, Cortez-Pinto H. Impaired renal function in morbid obese patients with nonalcoholic fatty liver disease. Liver Int. 2012. Feb;32(2):241-8.
10. Marcuccilli M, Choncho M. NAFLD and Chronic Kidney Disease. Int. J. Mol. Sci. 2016 Apr;17(4):562.
11. Musso G, Cassader M, Gambino R. Nonalcoholic steatohepatitis: emerging molecular targets and therapeutic strategies. Nat Rev Drug Discov. 2016;15:249-74.
12. Wang Y, Chen X, Song Y, Caballero B, Cheskin LJ. Association between obesity and kidney disease: a systemic review and meta-analysis. Kidney Int. 2008;73:19-33.
13. Yasui K, Sumida Y, Mori Y, Mitsuyoshi H, Minami M, Itoh Y. Nonalcoholic steatohepatitis and increased risk of chronic kidney disease. Metabolism. 2011 May;60(5):735-9. 

«Bulletin of problems biology and medicine» Issue 4 Part 2 (147), 2018 year, 120-124 pages, index UDK 616.61-002-008-06:616.36-003.826:613.25:615.099

10.29254/2077-4214-2018-4-2-147-120-124